119 results
424B3
BXRXQ
Baudax Bio, Inc.
22 Nov 23
Prospectus supplement
4:58pm
with potential collaborators and development partners;
our ability to defend any material litigation filed against us and avoid liabilities resulting … from any material litigation;
our ability to recruit or retain key scientific, technical, and management personnel or to retain our executive officers
8-K
EX-99.1
BXRXQ
Baudax Bio, Inc.
6 Oct 23
Departure of Directors or Certain Officers
8:00am
Securities Litigation Reform Act of 1995, that involve risks and uncertainties. Such forward-looking statements reflect Baudax Bio’s expectations about its
8-K
EX-99.1
BXRXQ
Baudax Bio, Inc.
29 Sep 23
Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors
7:01am
Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995
PRER14A
tfjkw3ml463hg
25 Aug 23
Preliminary revised proxy
4:01pm
8-K
EX-10.1
th0ba6
25 Aug 23
Entry into a Material Definitive Agreement
8:03am
DEFA14A
ssm8 z2i6y
21 Aug 23
Additional proxy soliciting materials
8:05am
8-K
EX-10.1
20e97bc7ip15 dx4g
21 Aug 23
Entry into a Material Definitive Agreement
8:00am
424B5
gjyj drkayyazhth
18 Aug 23
Prospectus supplement for primary offering
4:40pm
8-K
EX-99.1
hlllqe77yoz8lwr
16 Aug 23
Baudax Bio Reports Second Quarter 2023 Financial Results and Provides Business Update
8:11am
DEFA14A
EX-99.1
clv6shij o3dm95ljth
9 Aug 23
Additional proxy soliciting materials
5:28pm
DEFA14A
EX-99.2
v8m7x3la ln
9 Aug 23
Additional proxy soliciting materials
5:28pm